Evidence map›Paper›PMID 39088480›Full record

ArticlePLOS global public health2024

Pediatric and adolescent HIV viral load coverage and suppression rates in the context of the COVID-19 pandemic in 12 PEPFAR-supported sub-Saharan African countries in 2019 and 2020.

Deborah Carpenter, Marisa Hast, Nicole Buono, Susan Hrapcak, Kimi Sato, Rosemary Mrina, Mackenzie Hurlston Cox, Patricia Aladi Agaba, Alexandra C Vrazo, Hilary Wolf and 42 more

Abstract read
In one paragraph

Article in PLOS global public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

52 authors.

Deborah CarpenterDivision of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia.
Marisa HastDivision of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia.ORCID https://orcid.org/0000-0003-2471-6700
Nicole BuonoUnited States Agency for International Development, Washington, District of Columbia, United States of America.ORCID https://orcid.org/0009-0007-9176-9972
Susan HrapcakDivision of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia.
Kimi SatoDivision of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia.ORCID https://orcid.org/0000-0001-7970-6193
Rosemary MrinaWalter Reed Army Institute of Research, United States Military HIV Research Program, Silver Spring, Maryland, United States of America.
Mackenzie Hurlston CoxDivision of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia.
Patricia Aladi AgabaWalter Reed Army Institute of Research, United States Military HIV Research Program, Silver Spring, Maryland, United States of America.
Alexandra C VrazoUnited States Agency for International Development, Washington, District of Columbia, United States of America.
Hilary WolfUS Department of State, Office of the United States Global AIDS Coordinator, Washington, District of Columbia, United States of America.ORCID https://orcid.org/0000-0003-1435-382X
Emilia D RivadeneiraDivision of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia.
Judith D ShangDivision of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Yaounde, Cameroon.ORCID https://orcid.org/0000-0002-8978-6366
Magdalene Mange MayerDivision of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Yaounde, Cameroon.
Aka Herve PraoDivision of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Abidjan, Côte d'Ivoire.
Henri Onema LongumaDivision of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Kinshasa, Democratic Republic of Congo.
Constantin KabweDivision of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Kinshasa, Democratic Republic of Congo.ORCID https://orcid.org/0009-0008-6350-6371
Patricia Nyembo LwanaMinistry of Health, National AIDS Control Committee, Kinshasa, Democratic Republic of Congo.
Tsegaye TilahunUnited States Agency for International Development, Addis Ababa, Ethiopia.
Mamorapeli Ts'oeuDivision of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Maseru, Lesotho.
Immaculate MutisyaDivision of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Nairobi, Kenya.
Lennah Nyabiage OmotoDivision of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Nairobi, Kenya.ORCID https://orcid.org/0009-0003-6545-4249
Jessica Greenberg CowanDivision of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Maputo, Mozambique.
Maria Ines Jorge Tomo de DeusDivision of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Maputo, Mozambique.
Omodele Johnson FagbamigbeDivision of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Nigeria.
Uzoma EneDivision of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Nigeria.ORCID https://orcid.org/0000-0002-4959-5151
Akudo IkpeazuFederal Ministry of Health, Abuja, Nigeria.
Mduduzi B NdlovuDivision of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Pretoria, South Africa.
Eva MatikoDivision of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Dar es Salaam, Tanzania.
Nicolas SchaadDivision of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Dar es Salaam, Tanzania.
Jema BisimbaUnited States Agency for International Development, Dar es Salaam, Tanzania.
Elizabeth LemaUnited States Agency for International Development, Dar es Salaam, Tanzania.
Kebby MusokotwaneDivision of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Lusaka, Zambia.
Talent MaphosaDivision of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Harare, Zimbabwe.
Buyile ButheleziUnited States Agency for International Development, Pretoria, South Africa.
Adegbenga OlarinoyeHJF Medical Research International, Abuja, Nigeria.
Ismail LawalUS Army Medical Research Directorate-Africa/ Walter Reed Army Institute of Research, Abuja, Nigeria.ORCID https://orcid.org/0009-0003-6168-1890
Solomon MukungunugwaUnited States Agency for International Development, Harare, Zimbabwe.
Janet Tulibonywa MwambonaWalter Reed Army Institute of Research (WRAIR), Dar es Salaam, Tanzania.
Teferi WondimuDivision of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Addis Ababa, Ethiopia.
Immaculate Anne KathureUnited States Agency for International Development, Nairobi, Kenya.
Onyeka Donald IgboelinaUnited States Agency for International Development, Abuja, Nigeria.
Valery Nxima NzimaUnited States Agency for International Development, Yaounde, Cameroon.
Rosine Grace BissaiUnited States Agency for International Development, Yaounde, Cameroon.
Matjeko LenkaUnited States Agency for International Development, Maseru, Lesotho.
Willibrord ShashaUnited States Agency for International Development, Abidjan, Côte d'Ivoire.
N'guetta-Kan OlivierUnited States Agency for International Development, Abidjan, Côte d'Ivoire.
Mѐrcia MatsinheUnited States Agency for International Development, Maputo, Mozambique.
Argentina WateUnited States Agency for International Development, Maputo, Mozambique.
Lingenda GodfreyUnited States Agency for International Development, Lusaka, Zambia.
Heather AlexanderDivision of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia.
George AlemnjiDivision of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia.
Shirley LecherDivision of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia.ORCID https://orcid.org/0000-0002-8954-9408

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The early period of the COVID-19 pandemic limited access to HIV services for children and adolescents living with HIV (C/ALHIV). To determine progress in providing care and treatment services, we describe viral load coverage (VLC) and suppression (VLS) (<1000 copies/ mL) rates during the COVID-19 pandemic in 12 United States President's Emergency Plan for AIDS Relief (PEPFAR)-supported countries. Data for children (0-9 years) and adolescents (10-19 years) on VLC and VLS were analyzed for 12 sub-Saharan African (SSA) countries between 2019 (pre-COVID-19) and 2020 (during COVID-19). We report the number of viral load (VL) tests, and percent change in VLC and VLS for patients on ART. For 12 countries, 181,192 children had a VL test during the pre-COVID-19 period compared with 177,683 December 2020 during COVID-19. VLC decreased from 68.8% to 68.3% overall. However, 9 countries experienced an increase ranging from a 0.7%-point increase for Tanzania and Zimbabwe to a 15.3%-point increase for Nigeria. VLS increased for all countries from 71.2% to 77.7%. For adolescents the number with a VL test increased from 377,342 to 402,792. VLC decreased from 77.4% to 77.1%. However, 7 countries experienced an increase ranging from 1.8% for Mozambique to 13.8% for Cameroon. VLS increased for all countries from 76.8% to 83.8%. This analysis shows variation in HIV VLC across 12 SSA countries. VLS consistently improved across all countries demonstrating resilience of countries during 2020. Countries should continue to improve clinical outcomes from C/ALHIV despite service disruptions that may occur during pandemic response.

Identifiers

PMID39088480
PMCPMC11293699

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.